221 related articles for article (PubMed ID: 23095259)
21. Long-term evolution of anti-ganglioside antibody levels in patient with chronic dysimmune neuropathy under IVIg therapy.
Matà S; Borsini W; Caldini A; De Scisciolo G; Piacentini S; Taiuti R
J Neuroimmunol; 2006 Dec; 181(1-2):141-4. PubMed ID: 17023053
[TBL] [Abstract][Full Text] [Related]
22. Long-term treatment with subcutaneous immunoglobulin in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a follow-up period up to 7 years.
Gentile L; Mazzeo A; Russo M; Arimatea I; Vita G; Toscano A
Sci Rep; 2020 May; 10(1):7910. PubMed ID: 32404895
[TBL] [Abstract][Full Text] [Related]
23. Treatment-responsive pudendal dysfunction in chronic inflammatory demyelinating polyneuropathy.
Bussemaker L; Schelhaas HJ; Overeem S; Hopman WP; Zwarts MJ
Neurology; 2007 Mar; 68(12):957-8. PubMed ID: 17372137
[No Abstract] [Full Text] [Related]
24. [Chronic demyelinating auto-immune acquired neuropathy: Lewis-Sumner syndrome].
Seoane JL; Espadaler JM; Téllez MJ
Rev Neurol; 2000 Mar 16-31; 30(6):525-8. PubMed ID: 10863725
[TBL] [Abstract][Full Text] [Related]
25. Long-term effects of intravenous immunoglobulin in CIDP.
Vucic S; Black K; Baldassari LE; Tick Chong PS; Dawson KT; Cros D
Clin Neurophysiol; 2007 Sep; 118(9):1980-4. PubMed ID: 17604689
[TBL] [Abstract][Full Text] [Related]
26. High dose subcutaneous immunoglobulin for idiopathic inflammatory myopathies and dysimmune peripheral chronic neuropathies treatment: observational study of quality of life and tolerance.
Hachulla E; Benveniste O; Hamidou M; Mouthon L; Schleinitz N; Lozeron P; Léger JM; Vial C; Viala K
Int J Neurosci; 2017 Jun; 127(6):516-523. PubMed ID: 27412148
[TBL] [Abstract][Full Text] [Related]
27. Impact of subcutaneous immunoglobulin on quality of life in patients with chronic inflammatory demyelinating polyneuropathy previously treated with intravenous immunoglobulin.
Vu T; Anthony N; Alsina R; Harvey B; Schleutker A; Farias J; Dang S; Suresh N; Gooch C
Muscle Nerve; 2021 Sep; 64(3):351-357. PubMed ID: 34076265
[TBL] [Abstract][Full Text] [Related]
28. Long-term therapy with high doses of subcutaneous immunoglobulin in multifocal motor neuropathy.
Harbo T; Andersen H; Jakobsen J
Neurology; 2010 Oct; 75(15):1377-80. PubMed ID: 20938030
[TBL] [Abstract][Full Text] [Related]
29. [Treatment's initiation in chronic inflammatory demyelinating polyradiculopathy (CIDP)].
Uzenot D; Azulay JP; Pouget J
Rev Neurol (Paris); 2007 Sep; 163 Spec No 1():3S68-76. PubMed ID: 18087233
[TBL] [Abstract][Full Text] [Related]
30. [Multifocal motor neuropathy: a retrospective study of the response to high-dose intravenous immunoglobulin (IVIg) and current perspectives for diagnosis and treatment].
Léger JM; Viala K; Maisonobe T; Bouche P
Bull Acad Natl Med; 2007 Oct; 191(7):1395-407; discussion 1407-9. PubMed ID: 18447061
[TBL] [Abstract][Full Text] [Related]
31. [Intermittent intravenous immunoglobulin infusion prevented relapses in patients with remission-exacerbation type chronic inflammatory demyelinating polyradiculoneuropathy].
Kanda F; Sekiguchi K; Oishi K; Hamaguchi H; Mitsui S; Kobessho H; Higuchi M; Shirafuji T; Ishihara H
Rinsho Shinkeigaku; 2006 Mar; 46(3):236-8. PubMed ID: 16642939
[TBL] [Abstract][Full Text] [Related]
32. Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single-blinded cross-over trial.
Harbo T; Andersen H; Hess A; Hansen K; Sindrup SH; Jakobsen J
Eur J Neurol; 2009 May; 16(5):631-8. PubMed ID: 19236457
[TBL] [Abstract][Full Text] [Related]
33. Multifocal motor sensory demyelinating neuropathy: inflammatory demyelinating polyradiculoneuropathy.
Oh SJ; LaGanke C; Powers R; Wolfe GI; Quinton RA; Burns DK
Neurology; 2005 Nov; 65(10):1639-42. PubMed ID: 16301495
[TBL] [Abstract][Full Text] [Related]
34. Sensory loss in multifocal motor neuropathy: a clinical and electrophysiological study.
Lambrecq V; Krim E; Rouanet-Larrivière M; Lagueny A
Muscle Nerve; 2009 Feb; 39(2):131-6. PubMed ID: 19127532
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and Tolerability of Intravenous Immunoglobulin and Subcutaneous Immunoglobulin in Neurologic Diseases.
Chen Y; Wang C; Xu F; Ming F; Zhang H
Clin Ther; 2019 Oct; 41(10):2112-2136. PubMed ID: 31445679
[TBL] [Abstract][Full Text] [Related]
36. Chronic inflammatory demyelinating polyneuropathy in a patient with hyperIgEaemia.
Kimura A; Yoshino H; Yuasa T
J Neurol Sci; 2005 Apr; 231(1-2):89-93. PubMed ID: 15792827
[TBL] [Abstract][Full Text] [Related]
37. Long-term treatment of chronic inflammatory demyelinating polyradiculoneuropathy with plasma exchange or intravenous immunoglobulin.
Choudhary PP; Hughes RA
QJM; 1995 Jul; 88(7):493-502. PubMed ID: 7633875
[TBL] [Abstract][Full Text] [Related]
38. IgPro20, the Polyneuropathy and Treatment with Hizentra
Berger M; Harbo T; Cornblath DR; Mielke O
Immunotherapy; 2018 Aug; 10(11):919-933. PubMed ID: 29764262
[TBL] [Abstract][Full Text] [Related]
39. Immunoglobulin administration for the treatment of CIDP: IVIG or SCIG?
Allen JA; Gelinas DF; Freimer M; Runken MC; Wolfe GI
J Neurol Sci; 2020 Jan; 408():116497. PubMed ID: 31765922
[TBL] [Abstract][Full Text] [Related]
40. Atypical childhood chronic inflammatory demyelinating polyneuropathy.
Mohamed AR; Rodriguez-Casero MV; Ryan MM
Muscle Nerve; 2010 Aug; 42(2):293-5. PubMed ID: 20589891
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
